Hims Scraps $49 Weight-Loss Pill, Cedes Market to Novo Nordisk
Hims has discontinued its $49 over-the-counter weight-loss pill, halting further sales and removing the product from its pipeline due to underwhelming uptake. The decision may weaken near-term revenue growth and cede weight-management share to larger rivals such as Novo Nordisk.
1. Pill Abandonment Details
Hims has discontinued its $49 over-the-counter weight-loss pill, halting production and pulling the product from its distribution channels after sales fell short of targets. The move reflects a strategic retreat from a segment that failed to gain sufficient consumer traction.
2. Strategic and Market Impact
By exiting the weight-loss pill market, Hims risks dampening its personal wellness revenue and may need to invest in alternative offerings to sustain growth. This withdrawal also strengthens competitors’ positions, with Novo Nordisk poised to capture additional market share in the weight management space.